• Interface Biologics, Inc.

  Participated · Series B · Jan 2011

  Interface Biologics is a commercial-stage, privately held developer of biomedical-polymer technologies focused on improving the safety and effectiveness of medical devices. Its primary technology areas are surface modifying macromolecules and polymer-enabled combination drug-delivery devices. The company is a University of Toronto spinoff and is located at the MaRS Centre in Toronto. Management says the financing will help accelerate commercialization of its polymer technologies and the products they enable. The company has existing strategic and financial backers and is pursuing continued commercial development of its technology platforms. Interface Biologics is a University of Toronto spinoff focused on anti-thrombogenic devices that reduce thrombosis without heparin, anti-infective polymers, and programmable combination drug-delivery devices. The company is led by CEO Tom Reeves and is located at the MaRS Centre in Toronto. Founded in 2001, IBI intends to use the recent financing to fund clinical trials and commercialization efforts. The financing followed a report by the Ontario Bioscience Industry Organization presented to the Government of Ontario in 2010. Funding for the round is managed by the Investment Accelerator Fund-Life Sciences (IAF-LS). The IAF-LS program is delivered by MaRS and is funded by the Government of Ontario to accelerate life sciences companies. Interface Biologics develops biomedical-polymer technology to improve the safety and effectiveness of medical devices. Its primary technology focus areas are anti-thrombogenic devices that reduce thrombosis without the need for heparin, anti-infective polymers, and programmable combination drug-delivery devices. The company is a University of Toronto spinoff and is located at the MaRS Centre in Toronto. It is a commercial-stage company working to expand applications of its polymer platform. Management says the recent financing will allow the company to reach cash-flow breakeven. The company is seeking an additional $3–5m to facilitate development of other applications.

No current team members are available.